Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2

Synthetic DNA toolkit expands scientists’ ability to recognize genetic targets

A new method for recognizing and targeting DNA that dramatically expands the range of genetic sequences scientists can identify has been developed by experts at the University of Portsmouth. Published this week in Nature Communications, the research opens new possibilities for gene-targeting technologies, molecular diagnostics and DNA nanotechnology.

Dr. David Rusling, associate professor in bioengineering from the University of Portsmouth’s School of Medicine, Pharmacy and Biomedical Sciences, said, Our lab develops synthetic molecules that can recognize and bind to unique gene sequences. By introducing synthetic DNA bases into these molecules, we’ve been able to significantly improve how they recognize their targets.

I’ve worked in this area for around 20 years, and this is the first time we’ve had a system that combines strong recognition under physiological conditions with building blocks that are commercially available to other researchers.

Artificial DNA tiles could deliver drugs and monitor neurons non-disruptively

Living cells constantly exchange ions (i.e., charged particles) via the thin barrier that surrounds their interior, known as the outer membrane. Neuroscientists and medical researchers have long been trying to devise effective methods to measure this exchange of ions, which is known to be associated with communication between neurons and various other crucial physiological processes.

While techniques developed so far work relatively well, they rely on inserting tiny pipettes or electrodes into cells. These tools inevitably pierce the cells’ outer membranes, damaging cells and disrupting the intracellular milieu and machinery.

Researchers at Purdue University and University of Illinois Urbana-Champaign recently nanoengineered new biohybrid devices based on artificial DNA that could be used to track electrical signals sent or received by cells without breaking through the membrane and disrupting their functions.

Single-dose LSD drug successfully treats depression in key human trial

Disclaimer: Do NOT attempt without proper medical supervision.

In a paradigm-shifting breakthrough, Phase III clinical trials of DT120 — a novel, pharmaceutical-grade formulation of LSD — have demonstrated unprecedented efficacy in treating Major Depressive Disorder (MDD) following just a single dose. The study, encompassing 149 patients, revealed that a one-time administration of DT120 significantly outperformed a placebo, achieving the trial’s primary endpoint by reducing MADRS depression scores by an 8-point margin at six weeks. Remarkably, patients experienced rapid therapeutic relief within just one week, showcasing a massive 14-point advantage over the placebo group. Unlike conventional daily antidepressants that often take weeks to manifest effects, DT120 delivers profound and sustained symptom reduction from a single intervention. Hailed by Definium Therapeutics’ CEO Rob Burrow as a potential “best-in-class” therapy, these groundbreaking findings not only pave the way for expedited regulatory approval but also underscore the transformative potential of psychedelics to fundamentally revolutionize modern mental health care.

Definium Therapeutics has announced strong results in a phase 3 trial of its single-dosed lysergide (LSD) drug DT120 in treating adults with major depressive disorder (MDD), meeting its primary goal and all key secondary efficacy endpoints in the first trial of its kind.

The results come from the Emerge trial, a randomized, double-blind, placebo-controlled study featuring 149 participants aged 18 to 74 years enrolled across 20 sites. The participants all met specific MDD measures. They needed to have a DSM-5-confirmed diagnosis of MDD, a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 26 and a Clinical Global Impression–Severity (CGI-S) score of at least 4 at screening and baseline.

The study examined the effectiveness of a single 100 µg dose of DT120 ODT compared with a placebo in alleviating MDD symptoms. In 2023, we covered an earlier trial of lysergide, which had shown positive results in treating general anxiety disorder (GAD).

Lab-Grown Organs: Revolutionizing Transplants!

Discover the groundbreaking world of lab-grown organs in our latest YouTube Shorts! In “Lab-Grown Organs: Revolutionizing Transplants,” we explore how scientists are utilizing bioprinting, scaffold tissue engineering, and induced pluripotent stem cells to create functional organs like kidneys, livers, and hearts. This innovative approach not only eliminates transplant waiting lists but also uses a patient’s own cells, reducing the risk of rejection. Join us as we unveil the future of organ transplantation and the incredible advancements in organogenesis!

If you find this video enlightening, don’t forget to like and share it with your friends!

#LabGrownOrgans #TransplantRevolution #Bioprinting #Organogenesis #MedicalInnovation.

Follow me on ✅ X — x.com/ComputerB0B

#ai

Autism study reveals shared brain cell changes during early development

Hundreds of genes have been linked to autism, yet the precise molecular and cellular mechanisms behind it remain largely unclear. A new study published in Nature, led by Gaia Novarino at the Institute of Science and Technology Austria (ISTA), aims to uncover these mechanisms-and in doing so, might lay the groundwork for developing medical therapies.

Autism spectrum conditions, often abbreviated as ASD in scientific and medical literature, are, for example, neurodevelopmental disorders such as epilepsy or intellectual disability. The underlying changes begin during early brain development, while the first signs often become apparent in early childhood and can persist throughout life.

Anatomically accurate digital twin of 2-year-old’s brain uncovers neural signatures linked to autism

For decades, researchers have been trying to understand the biological roots of autism spectrum disorder (ASD), a common neurodevelopmental condition that shapes how people communicate, learn and interact with the world. One of the major hurdles is that the brain’s neural networks are extraordinarily complex. Existing models still lack the detail needed to capture both the brain’s structure and its dynamic activity in a unified manner.

In a recent study published in PLOS Digital Health, researchers created a new system called FEDE (high FidElity Digital brain modEl) that builds a digital twin, a detailed computer replica or virtual copy of a real-world object. In this study, it was a virtual copy of the brain of a 2-year-old child with ASD.

To build FEDE, researchers combined maps of the child’s brain structure obtained using MRI with mathematical modeling to create a digital brain that can simulate both how the brain is built and how it functions.

/* */